Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting CD93 on Monocytes revitalizes Anti-Tumor Immunity by Enhancing the Function and Infiltration of CD8+ T Cells

ABSTRACT: Targeting CD93 on Monocytes revitalizes Anti-Tumor Immunity by Enhancing the Function and Infiltration of CD8+ T Cells

PROVIDER: PRJNA1154620 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30494936_1.fastq.gz	Fastqsanger.gz
	SRR30494936_2.fastq.gz	Fastqsanger.gz
	SRR30494937_1.fastq.gz	Fastqsanger.gz
	SRR30494937_2.fastq.gz	Fastqsanger.gz
	SRR30494938_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Targeting CD93 on Monocytes revitalizes Anti-Tumor Immunity by Enhancing the Function and Infiltration of CD8+ T Cells

Project description:In this study, we found that monocytes in the peritumoral tissues of HCC significantly increased levels of CD93 expression, and these CD93+ monocytes collocated with CD8+ T cells, whose density was much higher in peri-tumor than intra-tumor areas. In vitro experiments showed that glycolytic switch mediated tumor-induced CD93 up-regulation in monocytes via the Erk signaling pathway. CD93 on the one hand could enhance PD-L1 expression through the AKT-GSK3β axis, while on the other hand induce monocytes to produce versican, a type of matrix component which interacted with hyaluronan and collagens to inhibit CD8+ T cell migration. Consistently, levels of CD93+ monocytes positively correlated with the density of peritumoral CD8+ T cells while negatively correlated with that of intratumoral CD8+ T cells. Targeting CD93 on monocytes not only increased the infiltration and activation of CD8+ T cells, but also enhanced tumor sensitivity to anti-PD-1 treatment in mice in vivo.

2024-10-30 | GSE276062 | GEO

CD93+ and CD93- HSCs comparison

Project description:CD93+ and CD93- HSCs comparison

| PRJNA701025 | ENA

CD93+ and CD93- HSCs comparison [RNA-Seq]

Project description:CD93+ and CD93- HSCs comparison [RNA-Seq]

| PRJNA701026 | ENA

CD93+ and CD93- HSCs comparison [ATAC-Seq]

Project description:CD93+ and CD93- HSCs comparison [ATAC-Seq]

| PRJNA701027 | ENA

Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8<sup>+</sup> T cells.

Project description:BackgroundLimited activation and infiltration of CD8+ T cells are major challenges facing T cell-based immunotherapy for most solid tumors, of which the mechanism is multilayered and not yet fully understood.MethodsLevels of CD93 expression on monocytes from paired non-tumor, peritumor and tumor tissues of human hepatocellular carcinoma (HCC) were evaluated. The underlying mechanisms mediating effects of CD93+ monocytes on the inhibition and tumor exclusion of CD8+ T cells were studied through both in vitro and in vivo experiments.ResultsIn this study, we found that monocytes in the peritumoral tissues of HCC significantly increased levels of CD93 expression, and these CD93+ monocytes collocated with CD8+ T cells, whose density was much higher in peritumor than intratumor areas. In vitro experiments showed that glycolytic switch mediated tumor-induced CD93 upregulation in monocytes via the Erk signaling pathway. CD93 on the one hand could enhance PD-L1 expression through the AKT-GSK3β axis, while on the other hand inducing monocytes to produce versican, a type of matrix component which interacted with hyaluronan and collagens to inhibit CD8+ T cell migration. Consistently, levels of CD93+ monocytes positively correlated with the density of peritumoral CD8+ T cells while negatively correlated with that of intratumoral CD8+ T cells. Targeting CD93 on monocytes not only increased the infiltration and activation of CD8+ T cells but also enhanced tumor sensitivity to anti-PD-1 treatment in mice in vivo.ConclusionThis study identified an important mechanism contributing to the activation and limited infiltration of CD8+ T cells in solid tumors, and CD93+ monocytes might represent a plausible immunotherapeutic target for the treatment of HCC.

| S-EPMC11499807 | biostudies-literature

scRNAseq of monocytes from Trained immunity experiments

Project description:scRNAseq of monocytes from in vitro Trained immunity experiments stimulated by β-glucan (BG), uric acid (UA), muramyl dipeptide (MDP), oxidized low-density lipoprotein (oxLDL), or RPMI-Control, and respective samples restimulated with Lipopolysaccharide (LPS).

2021-09-30 | E-MTAB-9702 | biostudies-arrayexpress

Cd93

Project description:Rattus norvegicus Cd93, CD93 molecule [Source:RGD Symbol;Acc:621251], is differentially expressed in 31 experiment(s);

| ENSRNOG00000024799 | ExpressionAtlas

Cd93

Project description:Rattus norvegicus Cd93, CD93 molecule [Source:RGD Symbol;Acc:621251], is expressed in 6 baseline experiment(s);

| ENSRNOG00000024799 | ExpressionAtlas

scRNAseq of monocytes from Trained immunity experiments

Project description:scRNAseq of monocytes from Trained immunity experiments

| PRJEB40999 | ENA

Comparison of transcriptional profiles of (1) intestinal ILC3s isolated from WT and IL-17D-deficient mice; (2) CD93+ILC3s and CD93-ILC3s from WT mice

Project description:IL-17D/CD93 axis was essential for ILC3s hemostasis. In order to further understand how IL-17D-CD93 axis regulate ILC3s function, we conducted RNA-seq analysis of ILC3s.

2021-05-20 | GSE165788 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data